Could the approval of bevacizumab for advanced cervical cancer and platinum-resistant ovarian cancer last year lead to patient-specific therapies?
The FDA has approved olaparib, to be marketed under the name Lynparza, for the treatment of advanced ovarian cancer related to defective BRCA genes.
A new app, called ADNEX, helps distinguish between benign and malignant ovarian tumors, potentially improving triage and management decisions.
New research looking at complication rates and cost for oophorectomy and cystectomy favors conventional laparoscopy over robotic surgery.
The use of oral contraceptives in women with BRCA1/2 mutations was associated with a reduced risk of ovarian cancer.
The use of an enhanced recovery pathway for perioperative care in complex gynecological surgery can reduce length of hospital stay, need for narcotic pain control, and costs.
A new index using protein markers can identify ovarian cancer cases at high and low risk for recurrence and discriminate between short- and long-term survivors.
An innovative, individualized vaccine that may prolong the remission period of ovarian cancer survivors has been developed. Will it work?
These beautiful and often other-worldly photographs by pathologist Ed Uthman, MD, show both benign and malignant ovarian pathology.
New research shows that symptoms exist in even early-stage ovarian cancer, disproving the myth that it's a "silent killer." Barbara Goff, MD, presents the latest in symptom research, tips on what physicians should be looking for, and what's on the horizon for ovarian cancer screening.